TY - JOUR
T1 - Clinicopathologic features of colorectal carcinoma in HIV-positive patients
AU - Sigel, Carlie
AU - Cavalcanti, Marcela S.
AU - Daniel, Tanisha
AU - Vakiani, Efsevia
AU - Shia, Jinru
AU - Sigel, Keith
N1 - Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2016/7
Y1 - 2016/7
N2 - Background: Emerging evidence suggests differences in colorectal cancer in HIV-infected patients (HIV+) compared with HIV- patients. Microsatellite instability (MSI), occurring in a subset of colorectal cancer, is present at a higher rate in certain cancers in HIV+ patients. Colorectal cancer with MSI share some characteristics with those reported for HIV+ colorectal cancer. On this premise, we studied clinical and pathologic features of HIV+ colorectal cancer and evaluated for MSI using matched HIV- colorectal cancer controls. Methods: Two nested, matched cohorts were identified from a hospital-based cohort of colorectal cancer patients. HIV+ colorectal cancers were identified and random control patients were matched for selected characteristics. Mismatch repair protein (MMR) IHC was performed as the detection method for MSI. Variables were compared between cases and controls using fixedeffects logit modeling to account for matching. Results: We included 184 colorectal cancer samples (38 HIV+, 146 HIV- control). Median patient age at colorectal cancer onset was 55. When compared with HIV- colorectal cancer, HIV+ patients were more likely to have smoked (P = 0.001), have right-sided colorectal cancer (37% vs. 14%; P = 0.003), and tumor-infiltrating lymphocytes (TIL) above 50/10 high-power fields (21% vs. 7%). Therewas no difference inMMRprotein expression (P= 0.6). HIV+ colorectal cancer patients had reduced overall survival (P = 0.02) but no difference in progression-free survival. Conclusions: HIV+ patients developed colorectal cancer at a lower median age than population estimates, had a higher frequency of right-sided disease, and increased TILs, suggesting potential biologic differences compared with uninfected patients. Impact: Clinicopathologic differences in colorectal cancer of HIV+ persons may have implications for tumor pathogenesis.
AB - Background: Emerging evidence suggests differences in colorectal cancer in HIV-infected patients (HIV+) compared with HIV- patients. Microsatellite instability (MSI), occurring in a subset of colorectal cancer, is present at a higher rate in certain cancers in HIV+ patients. Colorectal cancer with MSI share some characteristics with those reported for HIV+ colorectal cancer. On this premise, we studied clinical and pathologic features of HIV+ colorectal cancer and evaluated for MSI using matched HIV- colorectal cancer controls. Methods: Two nested, matched cohorts were identified from a hospital-based cohort of colorectal cancer patients. HIV+ colorectal cancers were identified and random control patients were matched for selected characteristics. Mismatch repair protein (MMR) IHC was performed as the detection method for MSI. Variables were compared between cases and controls using fixedeffects logit modeling to account for matching. Results: We included 184 colorectal cancer samples (38 HIV+, 146 HIV- control). Median patient age at colorectal cancer onset was 55. When compared with HIV- colorectal cancer, HIV+ patients were more likely to have smoked (P = 0.001), have right-sided colorectal cancer (37% vs. 14%; P = 0.003), and tumor-infiltrating lymphocytes (TIL) above 50/10 high-power fields (21% vs. 7%). Therewas no difference inMMRprotein expression (P= 0.6). HIV+ colorectal cancer patients had reduced overall survival (P = 0.02) but no difference in progression-free survival. Conclusions: HIV+ patients developed colorectal cancer at a lower median age than population estimates, had a higher frequency of right-sided disease, and increased TILs, suggesting potential biologic differences compared with uninfected patients. Impact: Clinicopathologic differences in colorectal cancer of HIV+ persons may have implications for tumor pathogenesis.
UR - http://www.scopus.com/inward/record.url?scp=84977126636&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-15-1179
DO - 10.1158/1055-9965.EPI-15-1179
M3 - Article
C2 - 27197294
AN - SCOPUS:84977126636
VL - 25
SP - 1098
EP - 1104
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
SN - 1055-9965
IS - 7
ER -